• Browse
• Meine Registrierung (Login)
• Registrierung (frei)

Pharmaceutical News

• Teva Announces Tentative Approval Of Generic Seroquel Tablets
  Wed, 31 December 2008
  Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of AstraZeneca's antipsychotic agent Seroquel (Quetiapine Fumarate) Tablets, Eq. 25 mg base, 50 m ...
• New Report Highlights Dramatic Change In U.S. Drug Spending Trends, Policy Implications
  Wed, 31 December 2008
  A major reduction in real prescription drug spending growth has created a turning point in healthcare with several policy implications, according to a study published this month by the journal Health Affairs as a Web Exclusive. The report, Prescription Drug Spending Trends in the United States: Looking Beyond the Turning Poi ...
• New Paradigm For Medicinal Chemistry Offered By International Public-Private Partnership
  Sun, 28 December 2008
  The Wellcome Trust has announced a Â4.1 million investment in a new initiative to generate small molecule inhibitors - chemical probes - for 25 proteins involved in epigenetic signalling, and to release these probes into the public domain with no restriction on use. Early stage information sharing on chemical probes is highl ...
• NicOx Announces Results For TPI 1020 In COPD
  Sun, 28 December 2008
  NicOx S.A. (NYSE Euronext Paris: COX) announced the results of a phase 2a study for TPI 1020, conducted in 62 patients with Chronic Obstructive Pulmonary Disease (COPD) by its partner Topigen Pharmaceuticals Inc. TPI 1020 showed good overall safety and tolerability, although its activity profile was not significantly differe ...
• Northwest Biotherapeutics Reports Encouraging Data On First Patients Who Have Completed ...
  Sun, 28 December 2008
  (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) Northwest Biotherapeutics, Inc. (NWBT) announced encouraging data on clinical responses in the first two case reports of patients who have completed the Company's Phase I/II clinical trial with DCVax(R)-L personalized cancer vaccine for recurrent, metastatic ovarian cancer.
• FDA Requires Additional Data For Seroquel XR Supplemental New Drug Application
  Sat, 27 December 2008
  The U.S. FDA (Food and Drug Administration) has asked AstraZeneca, the makers of Seroquel XR (quetiapine fumarate), for additional information for its extended release tablets for the treatment of MDD (Major Depressive Disorder) in adult patients. The FDA's CRL (Complete Response Letter) was sent to AstraZeneca on 24th Dec ...
• Roche Brings Together Asia's Leading Academic Researchers In Drug Delivery Symposium
  Sat, 27 December 2008
  Roche brought together more than 70 leading experts from research institutes and universities across Asia at its second Drug Delivery Symposium held in Shanghai, China early in December. The invited academics were selected for their leading-edge, innovative research that could contribute to solving numerous challenges in ...
• New Centre Launched Today To Spearhead UK Research In Synthetic Biology
  Sat, 27 December 2008
  Programming biological cells so that they behave like engineering parts is the focus of research at a new UK centre launched today, thanks to an Â8 million grant from the Engineering and Physical Sciences Research Council (EPSRC). The new centre will focus on synthetic biology. This is a field in which engineers work with ...
• Phase III Study Showed Rituxan Decreased The Progression Of Joint Damage In Patients Wit ...
  Sat, 27 December 2008
  Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III clinical study of Rituxan (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint. In this study, known as IMAGE, patients received two infusions ...
• Glivec Receives US Approval As First Treatment To Reduce Risk Of Cancer Returning In Pat ...
  Sat, 27 December 2008
  Novartis announced that Glivec (imatinib) has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Glivec is now the only post-surgery treatment indicated to dela ...